Project Grant R01HL183814
Award Date 8/20/26
Completion Date 4/30/30
Dollars Obligated $866K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Institutes of Health National Heart Lung and Blood Institute awarded Brigham & Women's Hospital Inc. $1.789 million on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds integrative computational-experimental approaches to identify rare coding variants that influence lipid metabolism and cardiovascular disease risk. The research combines large-scale population cohort data with high-throughput functional screening using base and prime...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $133,220 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct an ancillary study characterizing the burden and nature of 11-beta-hydroxysteroid dehydrogenase type 2 (11βHSD2) insufficiency in people with diabetes at risk for chronic kidney disease. The study examines how cortisol-mediated mineralocorticoid receptor (MR) activation contributes to chronic kidney...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $492,250 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct data-driven phenotyping of obstructive sleep apnea and sex-specific cardiovascular consequences. The research integrates high-dimensional physiological and clinical data from the Mass General Brigham Health System electronic health record cohort, which includes over 144,000 patients with structured records...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $268,500 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct multi-omic and network analysis investigating the role of X-linked transcription factors in chronic obstructive pulmonary disease heterogeneity. The research applies gene regulatory network analysis to multi-omic datasets from blood and lung tissue across four large COPD cohort studies (COPDGene, LTRC,...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling as risk factors for heart failure with preserved ejection fraction (HFPEF). The research investigates whether the ratio of peak...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $894,314 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop improved prediction and mechanistic understanding of chronic obstructive pulmonary disease exacerbations by integrating multi-trait genetics, proteomics, and deep learning methods. The research comprises three specific aims. In Aim 1, the recipient will develop a multi-trait polygenic risk score integrating...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received a $131,886 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for August 31, 2030. The project, titled "Volume and Patient-Oriented Research in Chronic Kidney Disease (VAPOR-CKD)," develops and validates clinical research methodologies to improve assessment of volume...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $1,540,621 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial inflammation, C-terminal SRC kinase dysregulation, and fibrosis in early pulmonary arterial hypertension. The award funds research into molecular mechanisms regulating fibroproliferative pulmonary vascular remodeling in early PAH, with particular focus on patients with inflammatory...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $353,776 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 20, 2025. The award funds investigation of place-based factors contributing to sleep health disparities in the United States. The research links nationwide public health surveillance data to neighborhood-level factors using geographic information science to test whether individual-level and place-based factors...